Prior Anti-TNFα Exposure | HCP

IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)

SIMILAR ACR20 RESPONSE SEEN REGARDLESS OF PRIOR ANTI-TNFα EXPOSURE1,2*

PRIOR ANTI-TNFα
EXPOSURE

ACR20 RESPONSE BY PRIOR ANTI-TNFα EXPOSURE WAS A SUBGROUP ANALYSIS OF THE PRIMARY ENDPOINT (ACR20 RESPONSE AT WEEK 24) (NRI ANALYSIS)

DISCOVER 1: ACR20 RESPONSE RATES IN PATIENTS WITH NO PRIOR ANTI-TNFα EXPOSURE

ACR20 response by prior anti-TNFα exposure was not adjusted for multiplicity. Therefore, statistical significance has not been established.

DISCOVER 1: ACR20 RESPONSE RATES IN PATIENTS WITH PRIOR ANTI-TNFα EXPOSURE

View Study Design

ACR20 response by prior anti-TNFα exposure was not adjusted for multiplicity. Therefore, statistical significance has not been established.

NRI=nonresponder imputation; TNF=tumor necrosis factor.

*Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent due to any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
Patients with missing data were considered nonresponders.

References: 1. Data on File. Janssen Biotech, Inc. 2. Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naïve or had previously received TNFα inhibitor treatment (DISCOVER 1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30265):1-11.